A review and meta-analysis of corneal cross-linking for post-laser vision correction ectasia.
A review and meta-analysis of corneal cross-linking for post-laser vision correction ectasia.
复制标题
DOI：
10.1016/j.joco.2017.02.008
复制
发表时间：
2017-09
影响因子：
1.5
通讯作者：
Han Y
中科院分区：
文献类型：
--
作者：
Wan Q;Wang D;Ye H;Tang J;Han Y
本研究的目的是回顾准分子激光屈光手术后角膜交联治疗角膜扩张症的安全性和稳定性。通过系统地检索PubMed、Embase、Web of Science和参考文献列表来确定符合条件的研究。meta分析采用Stata 12.1软件。主要结局参数包括矫正远视力（CDVA）、未矫正视力（UCVA）、最大角膜度数（Kmax）和最小角膜度数（Kmin）、角膜表面规则性指数（SRI）、角膜表面不对称指数（SAI）、圆锥角膜预测指数（KPI）、角膜厚度和内皮细胞计数的变化。疗效评估采用加权平均差（WMD）和95%可信区间（CI）对感兴趣的结果的绝对变化进行评估。meta分析纳入了7项研究，涉及118例在激光辅助原位角膜磨除术（LASIK）或光屈光性角膜切除术（PRK）后使用CXL治疗进行性扩张的患者（140眼，随访时间从12个月到62个月）。合并结果显示，CXL后Kmax和Kmin值无显著差异（WMD = 0.584, 95% CI:−0.289 ~ 1.458,P = 0.19, WMD = 0.466, 95% CI:−0.625 ~ 1.556,P = 0.403）。CXL后CDVA明显改善（WMD = 0.045; 95% CI: 0.010 ~ 0.079; P = 0.011），而UCVA无统计学差异（WMD = 0.011; 95% CI: - 0.055 ~ 0.077; P = 0.746）。SRI、SAI和KPI的变化无统计学意义（WMD = 0.116; 95% CI:−0.090 ~ 0.322;P = 0.269; WMD = 0.240; 95% CI:−0.200 ~ 0.681;P = 0.285; WMD = 0.045; 95% CI:−0.001 ~ 0.090;P = 0.056）。内皮细胞计数和角膜厚度没有恶化（WMD = 12.634; 95% CI:−29.460 ~ 54.729;P = 0.556; WMD = 0.657; 95% CI:−9.402 ~ 10.717;P = 0.898）。研究表明，CXL是稳定准分子激光屈光手术后角膜扩张症的一种有前景的治疗方法。需要进一步的长期随访研究来评估CXL效果的持久性。
The aim of this study was to review the safety and stability of cornea cross-linking (CXL) for the treatment of keratectasia after Excimer Laser Refractive Surgery. Eligible studies were identified by systematically searching PubMed, Embase, Web of Science and reference lists. Meta-analysis was performed using Stata 12.1 software. The primary outcome parameters included the changes of corrected distant visual acuity (CDVA), uncorrected visual acuity (UCVA), the maximum keratometry value (Kmax) and minimum keratometry value (Kmin), the surface regularity index (SRI), the surface asymmetry index (SAI), the keratoconus prediction index (KPI), corneal thickness, and endothelial cell count. Efficacy estimates were evaluated by weighted mean difference (WMD) and 95% confidence interval (CI) for absolute changes of the interested outcomes. Seven studies involving 118 patients treated with CXL for progressive ectasia after laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) (140 eyes; the follow-up time range from 12 to 62 months) were included in the meta-analysis. The pooled results showed that there were no significant differences in Kmax and Kmin values after CXL (WMD = 0.584; 95% CI: −0.289 to 1.458; P = 0.19; WMD = 0.466; 95% CI: −0.625 to 1.556; P = 0.403, respectively). The CDVA improved significantly after CXL (WMD = 0.045; 95% CI: 0.010 to 0.079; P = 0.011), whereas UCVA did not differ statistically (WMD = 0.011; 95% CI: −0.055 to 0.077; P = 0.746). The changes were not statistically significant in SRI, SAI, and KPI (WMD = 0.116; 95% CI: −0.090 to 0.322; P = 0.269; WMD = 0.240; 95% CI: −0.200 to 0.681; P = 0.285; WMD = 0.045; 95% CI: −0.001 to 0.090; P = 0.056, respectively). Endothelial cell count and corneal thickness did not deteriorate (WMD = 12.634; 95% CI: −29.460 to 54.729; P = 0.556; WMD = 0.657; 95% CI: −9.402 to 10.717; P = 0.898, respectively). The study showed that CXL is a promising treatment to stabilize the keratectasia after Excimer Laser Refractive Surgery. Further long-term follow-up studies are necessary to assess the persistence of the effect of the CXL.